(Q34112687)

31 July 2017

1 reference

title

New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin (English)

1 reference

31 July 2017

Sheryl Zelenitsky

4

0 references

George G Zhanel

1

object named as

George G Zhanel

1 reference

31 July 2017

10

James A Karlowsky

1 reference

31 July 2017

Divna Calic

2

1 reference

31 July 2017

Frank Schweizer

3

1 reference

31 July 2017

Heather Adam

5

1 reference

31 July 2017

Philippe R S Lagacé-Wiens

6

1 reference

31 July 2017

Ethan Rubinstein

7

1 reference

31 July 2017

Alfred S Gin

8

1 reference

31 July 2017

Daryl J Hoban

9

1 reference

31 July 2017

publication date

1 May 2010

1 reference

31 July 2017

1 reference

31 July 2017

volume

70

1 reference

31 July 2017

issue

7

1 reference

31 July 2017

page(s)

859-886

1 reference

Origin, structure, and activity in vitro and in vivo of dalbavancin

31 July 2017

cites work

1 reference

12 December 2020

Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria

1 reference

12 December 2020

Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.

1 reference

12 December 2020

Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms

1 reference

12 December 2020

Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic

1 reference

12 December 2020

The gene cluster for the biosynthesis of the glycopeptide antibiotic A40926 by nonomuraea species

1 reference

12 December 2020

In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe

1 reference

12 December 2020

Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model

1 reference

12 December 2020

Pharmacokinetics and excretion of dalbavancin in the rat.

1 reference

12 December 2020

Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose

1 reference

12 December 2020

Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis

1 reference

12 December 2020

In vitro activity of LY333328 (oritavancin) against Gram-positive aerobic cocci and synergy with ciprofloxacin against enterococci

1 reference

12 December 2020

Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study

1 reference

12 December 2020

Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).

1 reference

12 December 2020

Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies

1 reference

12 December 2020

1 reference

12 December 2020

Telavancin: a novel lipoglycopeptide antibiotic

1 reference

12 December 2020

Oritavancin for skin infections

1 reference

12 December 2020

Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions

1 reference

12 December 2020

Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens.

1 reference

12 December 2020

Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists

1 reference

12 December 2020

Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006.

1 reference

12 December 2020

Dalbavancin: a new lipoglycopeptide antibiotic

1 reference

12 December 2020

Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation

1 reference

12 December 2020

Vancomycin and oritavancin have different modes of action in Enterococcus faecium

1 reference

12 December 2020

Postantibiotic effects of telavancin against 16 gram-positive organisms

1 reference

12 December 2020

Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium.

1 reference

12 December 2020

New agents for Gram-positive bacteria

1 reference

12 December 2020

Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections

1 reference

12 December 2020

Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria

1 reference

12 December 2020

Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States

1 reference

12 December 2020

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus

1 reference

12 December 2020

Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres

1 reference

12 December 2020

Bactericidal activity and resistance development profiling of dalbavancin

1 reference

12 December 2020

Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria

1 reference

12 December 2020

In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative

1 reference

12 December 2020

Structure, biochemistry and mechanism of action of glycopeptide antibiotics

1 reference

12 December 2020

Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections

1 reference

12 December 2020

Glycopeptide antibiotics: from conventional molecules to new derivatives

1 reference

12 December 2020

Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters

1 reference

12 December 2020

Pharmacodynamics of Oritavancin (LY333328) in a Neutropenic-Mouse Thigh Model of Staphylococcus aureus Infection

1 reference

12 December 2020

Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50.

1 reference

12 December 2020

Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus

1 reference

12 December 2020

Telavancin: a novel lipoglycopeptide for serious gram-positive infections

1 reference

12 December 2020

Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity

1 reference

12 December 2020

Antibiotic susceptibility among Staphylococcus epidermidis isolated from prosthetic joint infections with special focus on rifampicin and variability of the rpoB gene

1 reference

12 December 2020

Telavancin: a novel lipoglycopeptide antimicrobial agent

1 reference

12 December 2020

Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin

1 reference

12 December 2020

Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates

1 reference

12 December 2020

Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci.

1 reference

12 December 2020

Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with persistent bacteraemia and endocarditis

1 reference

12 December 2020

Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia

1 reference

12 December 2020

Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections

1 reference

12 December 2020

In vivo pharmacodynamic activity of the glycopeptide dalbavancin

1 reference

12 December 2020

Oritavancin: a new avenue for resistant Gram-positive bacteria

1 reference

12 December 2020

Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens

1 reference

12 December 2020

Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States

1 reference

12 December 2020

Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus.

1 reference

12 December 2020

Review of dalbavancin, a novel semisynthetic lipoglycopeptide

1 reference

12 December 2020

Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin

1 reference

12 December 2020

Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.

1 reference

12 December 2020

Ultrastructural effects of oritavancin on methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus

1 reference

12 December 2020

In vitro activity of telavancin against resistant gram-positive bacteria

1 reference

12 December 2020

Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections.

1 reference

12 December 2020

Hexapeptide derivatives of glycopeptide antibiotics: tools for mechanism of action studies

1 reference

12 December 2020

Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing

1 reference

12 December 2020

Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia

1 reference

12 December 2020

Dalbavancin: a novel antimicrobial

1 reference

12 December 2020

Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects

1 reference

12 December 2020

Mechanism of action of oritavancin and related glycopeptide antibiotics

1 reference

12 December 2020

Vancomycin resistance in gram-positive cocci

1 reference

12 December 2020

Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system

1 reference

12 December 2020

Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.

1 reference

12 December 2020

Tissue penetration of telavancin after intravenous administration in healthy subjects

1 reference

12 December 2020

Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus

1 reference

12 December 2020

10.2165/11534440-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1048874194

0 references

1 reference